A federal jury in Delaware put US biotech major Amgen (Nasdaq: AMGN) on the hook Thursday for at least $271.2 million in ...

Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, with atherosclerotic cardiovascular ...

A new study conducted at Cedars-Sinai reveals how the cholesterol-reducing drug evolocumab prevents heart attacks in people ...

1 Department of Cardiology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China 2 Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of ...

Notable contributors included Repatha (evolocumab) for hypercholesterolemia and hyperlipidemia, Blincyto (blinatumomab) for B-cell acute lymphocytic leukaemia, recently approved in June 2024, and ...

Notable contributors included Repatha (evolocumab) for hypercholesterolemia and hyperlipidemia, Blincyto (blinatumomab) for B-cell acute lymphocytic leukaemia, recently approved in June 2024 ...

1 Center for Endocrine Metabolic and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China 2 Beijing Key Laboratory of Diabetes Prevention and Research Care, Beijing Luhe ...

Repatha (evolocumab) is a brand-name subcutaneous injection that isn’t known to interact with alcohol, other drugs, or supplements. However, Repatha has health-related interactions that are ...

Hospital Moinhos de Vento, Moinhos de Vento College of Health Sciences, Porto Alegre, Brazil (A.Z., A.L.F.K.). Hospital Moinhos de Vento, Moinhos de Vento College of ...

In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab ...